SUSTAINABILITY REPORT 2013-15

People Overview Self Managed Teams Mechanisation Safety Overview The Parivartan     Journey Progress on     Roadmap Incident Statistics Robust Governance Standardised     Processes Enhanced Awareness Capability Building Safety Infrastructure Safety Audits Quality Overview Top-down    Accountability Quality by Design Quality Culture     Transformation Quality Assurance Quality     Best Practices All Time Audit     Readiness Availability Overview Strategic Sourcing Risk Management Product    Rationalisation Success stories Environment Overview Roadmap Energy Management Emissions Water Waste Case Study KPIs Community Overview Focus Areas Education Livelihoods Healthcare Infrastructure     Initiatives Creating Change     Makers Productivity Overview Productivity Streams Case Study PACE Update Initiatives Engineering Excellence Overview Digitisation Automation Mechanisation Lean Manufacturing Capital Equipment Strategy Predictive Maintenance Continuous Improvement Overview Continuous     Improvement     at Work Best Practices Annexures GRI Index Acronyms Assurance Statement   Summary Report     PRODUCT RESPONSIBILITY PATIENT CENTRICITY Small Things Mean a Lot    |    Redesigning Packaging for Patient Convenience    |    PACT of Good Health   We aim to facilitate good health by going beyond the pill and offering a holistic product experience. We continuously engage with patients to understand their unfulfilled and unstated needs. Drawing from these rich insights, we innovate and enhance our products. Some such patient-centric interventions undertaken during the reporting period include:   Small Things Mean a Lot Patients suffering from Type-2 diabetes depend on Metformin as their first in line medicine. The pill was very big in size and hence uncomfortable to swallow. Thus some patients were skipping the medicine, while a large number were breaking it in half to get it down more easily. This is not advisable as it may affect the medicine's dissolution pattern. Recognising patients' needs, we decided to create a smaller pill that still packed the same impact. The major technical hurdle was reducing the size while ensuring that the right quantity of drug is made available in the blood stream. We worked with cross-functional teams across every domain to develop a solution. Our R&D, formulations, IP and marketing teams came up with Metsmall®. Now, patients find it easier to take Metsmall® and thus manage their disease effectively on a daily basis.